Invention Grant
- Patent Title: Method of treating nonalcoholic steatohepatitis by administering an antagonist human tumor necrosis factor receptor 1 (HUTNFR1) antibody
-
Application No.: US16766841Application Date: 2018-11-27
-
Publication No.: US11028178B2Publication Date: 2021-06-08
- Inventor: Heike Bantel , Klaus Pfizenmaier , Andreas Herrmann
- Applicant: BALIOPHARM AG
- Applicant Address: CH Basel
- Assignee: BALIOPHARM AG
- Current Assignee: BALIOPHARM AG
- Current Assignee Address: CH Basel
- Agency: Meunier Carlin & Curfman LLC
- Priority: EP17203853 20171127
- International Application: PCT/EP2018/082634 WO 20181127
- International Announcement: WO2019/102023 WO 20190531
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P1/16 ; A61P3/00 ; A61K39/395 ; A61K39/00 ; A61K45/06
Abstract:
An antibody specifically recognizing human tumor necrosis factor 1 (hu TNFR1), for use in treating nonalcoholic steatohepatitis (NASH) and disease conditions associated thereto.
Public/Granted literature
- US20200299396A1 ANTI-huTNFR1 THERAPY OF NONALCOHOLIC STEATOHEPATITIS Public/Granted day:2020-09-24
Information query
